Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants, 2026, Reeder et al

Nightsong

Nightsong

Senior Member (Voting Rights)
Abstract:

Background:​

Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time.

Objective:​

To evaluate the likelihood of improvement among persons with likely LC.

Design:​

Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]).

Setting:​

83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico.

Participants:​

1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection.

Measurements:​

The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points.

Results:​

An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar.

Limitation:​

Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement.

Conclusion:​

Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials.

Link (Annals of Internal Medicine, November 2026)
 
They assign participants to LC subtypes previously found with unsupervised clustering on symptoms. Subtype 5 (and maybe 3) are resembling MECFS.

1793664585252.webp
Subtype 5 has by far the lowest probability of improvement according to their primary outcome measure.
 

Attachments

  • 1793663999256.webp
    1793663999256.webp
    117.2 KB · Views: 13
Kilian_M said:
They assign participants to LC subtypes previously found with unsupervised clustering on symptoms. Subtype 5 (and maybe 3) are resembling MECFS.
Click to expand...
Per your second picture, all clusters except cluster 1 seem to have a high contribution from the PEM feature, so at face value I'd say they all resemble ME/CFS. I wonder how they defined and measured post-exertional malaise.
 
www.eurekalert.org

Half of long COVID patients see meaningful symptom improvement within three years

A prospective cohort study found that about half of people living with long COVID a year after their initial COVID-19 infection experienced a meaningful symptom improvement within three years, whereas a quarter experienced a complete remission.
www.eurekalert.org

News Release 2-Nov-2026

Half of long COVID patients see meaningful symptom improvement within three years​

Peer-Reviewed Publication
American College of Physicians


FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail

Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------

1. Half of long COVID patients see meaningful symptom improvement within three years

Abstract:
URL goes live when the embargo lifts

A prospective cohort study found that about half of people living with long COVID a year after their initial COVID-19 infection experienced a meaningful symptom improvement within three years, whereas a quarter experienced a complete remission. While the study shows that long COVID recovery is often gradual, the findings suggest a need for placebo-controlled studies examining therapeutic interventions given the large number of adults living with this condition. The study is published in Annals of Internal Medicine.



Researchers from Massachusetts General Hospital and colleagues followed 1,019 adults in the RECOVER-Adult cohort with likely long COVID 12 months after initial COVID-19 diagnosis to evaluate the likelihood of improvement in symptoms. Investigators tracked participants' symptoms over time via a commonly used long COVID research index, and assessed how many experienced sustained improvement, major symptom reduction, or complete remission of symptoms. By two years after initial infection, 36.2% of patients experienced a sustained symptom improvement, and by three years, 50.1% of participants experienced a sustained symptom improvement. Also by three years, 56.4% experienced substantial symptom reductions along with a good quality of life, and nearly 26.9% experienced complete remission. The findings suggest that recovery is possible for many patients, but they also highlight the need for clinical trials to develop effective treatments for those whose symptoms persist.



Media contacts: For an embargoed PDF, please contact Gabby Macrina at gmacrina@acponline.org. To contact corresponding author Harrison T. Reeder, PhD, please email Cassandra Falone at cfalone@mgb.org.
 
Dolphin said:
www.eurekalert.org

Half of long COVID patients see meaningful symptom improvement within three years

A prospective cohort study found that about half of people living with long COVID a year after their initial COVID-19 infection experienced a meaningful symptom improvement within three years, whereas a quarter experienced a complete remission.
www.eurekalert.org

News Release 2-Nov-2026

Half of long COVID patients see meaningful symptom improvement within three years​

Peer-Reviewed Publication
American College of Physicians


FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail

Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------

1. Half of long COVID patients see meaningful symptom improvement within three years

Abstract:
URL goes live when the embargo lifts

A prospective cohort study found that about half of people living with long COVID a year after their initial COVID-19 infection experienced a meaningful symptom improvement within three years, whereas a quarter experienced a complete remission. While the study shows that long COVID recovery is often gradual, the findings suggest a need for placebo-controlled studies examining therapeutic interventions given the large number of adults living with this condition. The study is published in Annals of Internal Medicine.



Researchers from Massachusetts General Hospital and colleagues followed 1,019 adults in the RECOVER-Adult cohort with likely long COVID 12 months after initial COVID-19 diagnosis to evaluate the likelihood of improvement in symptoms. Investigators tracked participants' symptoms over time via a commonly used long COVID research index, and assessed how many experienced sustained improvement, major symptom reduction, or complete remission of symptoms. By two years after initial infection, 36.2% of patients experienced a sustained symptom improvement, and by three years, 50.1% of participants experienced a sustained symptom improvement. Also by three years, 56.4% experienced substantial symptom reductions along with a good quality of life, and nearly 26.9% experienced complete remission. The findings suggest that recovery is possible for many patients, but they also highlight the need for clinical trials to develop effective treatments for those whose symptoms persist.



Media contacts: For an embargoed PDF, please contact Gabby Macrina at gmacrina@acponline.org. To contact corresponding author Harrison T. Reeder, PhD, please email Cassandra Falone at cfalone@mgb.org.
Click to expand...

Isn’t the big question ‘what are the differences between those that recover and those that don’t?
 
From Bluesky:
Long Covid Advocacy @longcovidadvoc.com
A new study on Long Covid recovery:

50% of people with Long Covid experienced meaningful symptom improvement within 3 yrs

27% achieved "complete remission"

Sounds promising?! Let's look a bit deeper/1

#medtwitter


Lowdown:

NIH-funded RECOVER study followed 1,019 participants who met criteria for likely Long Covid 12 months after infection.

It's valuable longitudinal data.

But there are important questions about symptom measurement, disease subtypes and definitions of recovery. /2

How did they measure?!

With the Long Covid Research Index (LCRI), a weighted score of (only!!?) 11 symptoms

Participants met the primary improvement outcome if their score fell below 11 at 2 consecutive visits, approximately 3 months apart.

There are issues with this: /3

Falling below a research threshold doesn't necessarily mean someone has recovered

A person could remain significantly disabled, experience fluctuating symptoms or have substantially reduced their activity to manage their illness⚠️

Symptom reduction is not recovery /4

Long Covid can follow a relapsing–remitting course, yet the study's primary outcome requires just 2!! visits below the symptom threshold.

Assessments every 3 months may miss significant fluctuations, crashes and deterioration between visits & after /5

Crucially, once someone meets the improvement threshold, they're counted as having achieved that outcome, even if they subsequently relapse.

The 50% figure therefore doesn't establish how many remained improved at three years, or how many experienced subsequent deterioration./6

More concerning is the definition of "complete remission".

Researchers classified participants as achieving this outcome when their LCRI score reached 0 at a single visit.

But the index measures only 11 symptoms, despite Long Covid involving a much broader number. /7

The study divides LC into 5 subtypes: smell/taste changes, chronic cough, brain fog, palpitations and multisystem symptoms

However, these are statistical symptom clusters, not clinically validated biological subtypes

They're ordered by increasing overall symptom frequency /8

Then there's PEM.

The researchers report that PEM and fatigue were common across all five subtypes.

It doesn't state the methods to determine PEM. BUT if it's the previous one RECOVER ENERGISE used it's REALLY broad. /9

We need to know reliably the proportion of those with Long Covid who have PEM - as PEM is the defining characteristic of ME.

Do most people with Long Covid have ME? Or are we conflating fatigue?

This is a huge problem in ME & now LC. We need better assessment. /10

The other crucial issue: pacing.

Someone with PEM may experience fewer crashes b/c they've drastically reduced their activity, not b/c their illness has improved.

Without assessing activity and functional capacity, how do we distinguish symptom management from recovery? /11

Missing data also matters.

They imputed 11–13% of intermittent missing follow-up visits, while participants who withdrew or were lost to follow-up were censored.

If those becoming more severely ill were disproportionately lost, improvement estimates could be biased. /12

None of this means the study is totally useless. But it shows the issue of questionnaire based studies in a super heterogeneous disease.

That the billions wasn't spent digging down into the biology means we are still relatively clueless. /13

And headline matters. If a big RECOVER study states 50% meaningfully improve and nearly a third enter remission. It can lead to minimisation of the problem as people assume 'most' recover 'naturally'.

This isn't looking at SUSTAINED recovery. It's a snapshot. /14

And even with the positive slant in this it still shows that a huge number of people are not recovering.

Even if we take the figures - 50% not meaningfully improving & 2/3rds not recovering is still a crisis. /15

Link to study:

acpjournals.org
Click to expand...
 
You must log in or register to reply here.
Back
Top Bottom